Unexplained Cardiac Uptake on 99mTc-MDP Bone Scan in a Patient with Prostate Cancer

Document Type : Case report

Authors

1 Division of Nuclear Medicine, Department of Radiology and Nuclear Medicine, University of Jordan, Amman, Jordan

2 Department of Radiology and Nuclear Medicine, University of Jordan, Amman, Jordan

3 Department of Nuclear Medicine, King Hussein Cancer Center, Amman, Jordan

4 Division of Cardiology, Department of Internal Medicine, University of Jordan, Amman, Jordan

10.22038/aojnmb.2025.85251.1609

Abstract

This case report presents a case of unusual diffuse cardiac uptake (Peruguni 3: uptake greater than rib uptake) on a 99mTc-methylene diphosphonate bone scan in an 83-year-old patient with metastatic prostate cancer which is almost resolved (Peruguni 1: uptake less than rib uptake) on a follow up bone scan about 4.4 months later.  Laboratory values and imaging were negative for cardiac amyloidosis and a thorough review of the patient's medical chart did not reveal any other possible causes, pharmacologic or otherwise, thus deeming the uptake non-specific. While increased non-specific cardiac 99mTc-diphosphanate uptake has been previously reported in elderly prostate cancer patients, possibly attributable to asymptomatic atherosclerosis, this explanation is unlikely considering that the uptake almost resolved within a relatively short period of time. It is clinically important to rule out amyloidosis in patients with increased cardiac uptake on bone scans. However, we believe that clinicians should also consider the possibility of non-specific uptake as a cause for cardiac uptake on bone scan, which would only require follow-up rather than medical intervention.

Keywords

Main Subjects

References

  1. Delaney FT, Dempsey P, Welaratne I, Buckley B, O’ Sullivan D, O’Connell M. Incidental cardiac uptake in bone scintigraphy: increased importance and association with cardiac amyloidosis. BJR Case Rep. 2021; 7(3): 20200161.
  2. Wong KK, Piert M. Dynamic bone imaging with 99mTc-labeled diphosphonates and 18F-NaF: mechanisms and applications. Journal of Nuclear Medicine. 2013; 54(4):590-9.
  3. Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, et al. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association. Circulation. 2020; 142(1):e7-e22.
  4. Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. 2016; 133(24): 2404-12.
  5. Castano A, Haq M, Narotsky DL, Goldsmith J, Weinberg RL, Morgenstern R, et al. Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis. JAMA Cardiology. 2016; 1(8):880-9.
  6. Maurer MS, Bokhari S, Damy T, Dorbala S, Drachman BM, Fontana M, et al. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ: Heart Failure. 2019; 12(9): e006075.
  7. Pilebro B, Suhr OB, Näslund U, Westermark P, Lindqvist P, Sundström T. 99mTc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis. Ups J Med Sci. 2016; 121(1):17-24.
  8. Stats MA, Stone JR. Varying levels of small micro calcifications and macrophages in ATTR and AL cardiac amyloidosis: implications for utilizing nuclear medicine studies to subtype amyloidosis. Cardiovascular 2016; 25(5): 413-7.
  9. Cook GJR, Azad G, Padhani AR. Bone imaging in prostate cancer: the evolving roles of nuclear medicine and radiology. Clin Transl Imaging. 2016; 4(6): 439-47.
  10. Melero-Polo J, Roteta-Unceta-Barrenechea A, Andrés-Gracia A, Pérez-Palacios R, Revilla-Martí P, Atienza-Ayala S, et al. Incidental myocardial uptake in patients with prostate cancer: a challenging subject. European Journal of Medical and Health Sciences. 2024; 6(2): 90-5.
  11. Al-Nahhas AM, Jinnouchi S, Anagnostopoulos C, Hirsch W, Heary T, Mc Cready VR. Clinical significance of technetium-99m methylene diphosphonate myocardial uptake: association with carcinoma of the prostate. Eur J Nucl Med. 1995; 22(2):148-53.
  12. Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin. 2017; 67(2):93-99.
  13. Caobelli F, Paghera B, Pizzocaro C, Guerra UP. Extraosseous myocardial uptake incidentally detected during bone scan: report of three cases and a systematic literature review of extraosseous uptake. Nucl Med Rev. 2013; 16(2):82-7.
  14. Jones A, Keeling D. Benign myocardial uptake of hydroxymethylene diphosphonate: Nuclear Medicine Communications. 1994; 15(1):21-23.
  15. Chadrawar S, George M, Al-Akraa M, Herber M, Buscombe J. Myocardial uptake of Tc-99m HDP in a patient with prostate carcinoma. Nucl Med Rev Cent East Eur. 2009; 12(2):78-80.
  16. Kim MC, Ahn Y, Cho KH, Sim DS, Hong YJ, Kim JH, et al. Image of Statin-Induced Rhabdo-myolysis. Korean Circ J. 2020; 50(8): 738-9.
  17. Zerizer I, Cameron J, Kon OM, Kapse NA, Dhawan RT. Don’t blame the bones! Eur J Nucl Med Mol Imaging. 2011; 38(1): 191.
  18. Gandini A, Bauckneht M, Sofia L, Tomasello L, Fornarini G, Zanardi E. Cardiac metastasis from prostate cancer: a case study underlying the crucial role of the PSMA PET/CT. Diagnostics. 2023; 13(17): 2733.
  19. Lam KY, Dickens P, Chan AC. Tumors of the heart. A 20-year experience with a review of 12,485 consecutive autopsies. Arch Pathol Lab Med. 1993; 117(10): 1027-31.
  20. Demirel K, Sadic M, Korkmaz M, Comak A, Atilgan HI, Koca G. Diffuse Myocardial Uptake of 99mTc-HDP in Multiple Myeloma. Nucl Med Mol Imaging. 2013; 47(3): 208-11.
Asia Oceania Journal of Nuclear Medicine and Biology
Volume 13, Issue 2
July 2025
Pages 198-202

Files

Share

How to cite

Statistics